UroGen Pharma (URGN) EBT Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly EBT Margin came in at 55.63% in Q1 2026, up 15891.0% YoY from N/an in Q1 2025, and up 20.99% on a QoQ basis from 70.4% in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) EBT Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of EBT Margin data on file, last reported at 55.63% in Q1 2026.
- Quarterly EBT Margin rose 15891.0% year-over-year to 55.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.45% (up 4878.0% YoY) and the FY2025 annual result came in at 139.74%, down 252.0% from the prior year.
- EBT Margin rose to 55.63% in Q1 2026, from 70.4% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 55.63% in Q1 2026 to a low of 214.53% in Q1 2025.
- A 5-year average of 140.92% and a median of 152.71% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin sank 4933 bps — and 2026, when it soared 15891 bps.
- Tracing URGN's EBT Margin over 5 years: stood at 155.76% in 2022, then soared by 40 bps to 94.19% in 2023, then slumped by 51 bps to 141.92% in 2024, then jumped by 50 bps to 70.4% in 2025, then gained by 21 bps to 55.63% in 2026.
- The last three EBT Margin figures came in at 55.63% (Q1 2026), 70.4% (Q4 2025), and 125.18% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | -12.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.04% |
| Mar 31, 2026 | -55.63% |
| Dec 31, 2025 | -70.40% |
| Sep 30, 2025 | -125.18% |
| Jun 30, 2025 | -202.04% |
| Mar 31, 2025 | -214.53% |
| Dec 31, 2024 | -141.92% |
| Sep 30, 2024 | -93.56% |
| Jun 30, 2024 | -152.71% |
| Mar 31, 2024 | -171.62% |
| Dec 31, 2023 | -94.19% |
| Sep 30, 2023 | -104.97% |
| Jun 30, 2023 | -113.92% |
| Mar 31, 2023 | -175.62% |
| Dec 31, 2022 | -155.76% |
| Sep 30, 2022 | -156.07% |
| Jun 30, 2022 | -160.56% |
| Mar 31, 2022 | -206.92% |
| Dec 31, 2021 | -168.88% |
| Sep 30, 2021 | -266.15% |